Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application for Tzield (teplizumab-mzwv), allowing its use to delay stage 3 type 1 diabetes (T1D) onset in children as young as one year diagnosed with stage 2 T1D.
Novartis claims that the COMBI-d study of 423 patients is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination
These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aß), which are widely believed to play
The ENDEAR (A Phase III, Randomized, International Study Comparing the Efficacy and Safety of ENzalutamiDe in Combination With PaclitaxEl Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in
The study will explore if novel CIIE-identified targets, when formulated in the DepoVax delivery system, provide immunogenic responses against parasites that cause life-threatening malaria. The collaborators expect to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
